Aurobindo Pharma的子公司Eugia Pharma收到美国林业发展局为他们的Telangana设施发出的警告信。 Aurobindo Pharma's subsidiary Eugia Pharma receives a US FDA warning letter for their Telangana facility.

欧罗宾多制药公司的子公司Eugia Pharma Specialities Limited收到了美国FDA的警告信, Aurobindo Pharma's subsidiary, Eugia Pharma Specialities Limited, received a warning letter from the US FDA for their Telangana-based formulation manufacturing unit. 该设施曾于5月获得官方行动指示(OAI)地位。 The facility had previously received Official Action Indicated (OAI) status in May. Aurobindo Pharma表示警告信不会影响美国市场现有的供应, Aurobindo Pharma stated the warning letter will not impact existing supplies to the US markets and remains committed to working closely with the USFDA to enhance compliance.